The syndrome of inappropriate antidiuresis: Pathophysiology, clinical management and new therapeutic options

Nephron - Clinical Practice

Volumn 119, Issue 1, 2011, Pages

  Esposito, Pasquale ^a,b   Piotti, Giovanni ^a   Bianzina, Stefania ^a   Malul, Yehuda ^a   Dal Canton, Antonio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Antidiuretic hormone; Hyponatremia; Nephrogenic syndrome of inappropriate antidiuresis; Syndrome of inappropriate antidiuresis; Vaptans

Indexed keywords

AMLODIPINE; ARGIPRESSIN; CLARITHROMYCIN; CONIVAPTAN; DEMECLOCYCLINE; DESMOPRESSIN; FUROSEMIDE; HYPERTONIC SOLUTION; INDINAVIR; KETOCONAZOLE; LITHIUM CARBONATE; LIXIVAPTAN; PLACEBO; RITONAVIR; SATAVAPTAN; SIMVASTATIN; SODIUM; SODIUM CHLORIDE; TOLVAPTAN; UREA; VASOPRESSIN; WATER;

ANOREXIA; CLINICAL FEATURE; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE MARKER; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FEVER; FLUID BALANCE; GASTROINTESTINAL SYMPTOM; HEART VENTRICLE TACHYCARDIA; HORMONE ACTION; HORMONE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INJECTION SITE REACTION; INTERSTITIAL NEPHRITIS; LOADING DRUG DOSE; NAUSEA; NEPHROTOXICITY; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; POLLAKISURIA; POLYURIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SODIUM BALANCE; THIRST; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; WEAKNESS; XEROSTOMIA;

ANIMALS; BENZAZEPINES; DISEASE MANAGEMENT; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; NEUROPHYSINS; PROTEIN PRECURSORS; VASOPRESSINS; WATER-ELECTROLYTE BALANCE;

EID: 79958765509     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000324653     Document Type: Review

References (84)

1. Schwartz WB, Bennett W, Curelop S, Bartter FC: A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957; 23: 529-542.
2. Ellison DH, Berl T: The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356: 2064-2072. (Pubitemid 46789896)
3. Schally AV: Hormones of the neurohypophysis; in Lock W, Schally AV (eds): The Hypothalamus and Pituitary in Health and Disease. Springfield, Thomas, 1972, pp 154-171.
4. Tsujimoto M, Goto Y, Maruyama M, Hattori A: Biochemical and enzymatic properties of the M1 family of aminopeptidases involved in the regulation of blood pressure. Heart Fail Rev 2008; 13: 285-291.
5. Durr JA, Hoggard JG, Hunt JM, Schrier RW: Diabetes insipidus in pregnancy associated with abnormally high circulating vasopressinase activity. N Engl J Med 1987; 316: 1070-1074. (Pubitemid 17047297)
6. Ball SG: Vasopressin and disorders of water balance: The physiology and pathophysiology of vasopressin. Ann Clin Biochem 2007; 44: 417-431. (Pubitemid 351724650)
7. Altura BM, Altura BT: Actions of vasopressin, oxytocin, and synthetic analogs on vascular smooth muscle. Fed Proc 1984; 43: 80-86. (Pubitemid 14175721)
8. Thibonnier M, Conarty DM, Preston JA, et al: Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998; 449: 251-276. (Pubitemid 28566397)
9. Du Pasquier D, Loup F, Dubois-Dauphin M, et al: Binding sites for vasopressin in the human pituitary are associated with corticotrophs and may differ from other known vasopressin receptors. J Neuroendocrinol 1991; 3: 237-247.
10. Nielsen S, Frokler J, Marples D, Kwon T, et al: Aquaporins in the kidney from molecules to medicine. Physiol Rev 2002; 82: 205-244.
11. Bankir L: Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1A and V2 receptor-mediated effects. Cardiovasc Res 2001; 51: 372-390. (Pubitemid 32718586)
12. McKinley MJ, Mathai M, McAllen RM, et al: Vasopressin secretion: Osmotic and hormonal regulation by the lamina terminalis. J Neuroendocrinol 2004; 16: 340-347. (Pubitemid 38618651)
13. Baylis PH, Thompson CJ: Osmoregulation of vasopressin secretion and thirst in health and disease. Clin Endocrinol 1988; 29: 549-576.
14. Goetz KL, Zhu JL, Leadley RJ, et al: Hemodynamic and hormonal influences on the secretion of vasopressin; in Jard S, Jamison R (eds): Vasopressin. Montrouge, Libbey, 1991, pp 279-286.
15. Brooks VL, Keil LC, Reid IA: Role of the renin- angiotensin system in the control of vasopressin secretion in conscious dogs. Circ Res 1986; 58: 829-838. (Pubitemid 16094212)
16. Goldsmith SR, Dodge D, Cowley AW: Nonosmotic influences on osmotic stimulation of vasopressin in humans. Am J Physiol 1987; 252:H85-H88.
17. Kendler KS, Weitzman RE, Fisher DA: The effect of pain on plasma arginine vasopressin concentrations in man. Clin Endocrinol (Oxf) 1978; 8: 89-94. (Pubitemid 8321248)
18. Smith D, Moore K, Tormey W, et al: Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab 2004; 287:E1019-E1023. (Pubitemid 39382941)
19. Manoogian C, Pandian M, Ehrlich L, et al: Plasma atrial natriuretic hormone levels in patients with the syndrome of inappropriate antidiuretic hormone secretion. J Clin Endocrinol Metab 1988; 67: 571-575.
20. Levinsky NG, Davidson DG, Berliner RW: Changes in urine concentration during prolonged administration of vasopressin and water. Am J Physiol 1959; 196: 451-456.
21. Ecelbarger CA, Nielsen S, Olson BR: Role of renal aquaporins in escape from vasopressin induced antidiuresis in rat. J Clin Invest 1997; 99: 1852-1863. (Pubitemid 27175932)
22. Tian Y, Sandberg K, Murase T, et al: Vasopressin V2 receptor binding is down-regulated during renal escape from vasopressininduced antidiuresis. Endocrinology 2000; 141: 307-314. (Pubitemid 32260372)
23. Hoorn EJ, Zietse R: Hyponatremia revisited: Translating physiology to practice. Nephron Physiol 2008; 108: 46-59.
24. Jacob S, Spinler SA: Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006; 40: 1618-1622. (Pubitemid 44330206)
25. Coyle S, Penney MD, Masters PW, Walker BE: Early diagnosis of ectopic arginine vasopressin secretion. Clin Chem 1993; 39: 152-154. (Pubitemid 23034978)
26. De Bragança AC, Moyses ZP, Magaldi AJ: Carbamazepine can induce kidney water absorption by increasing aquaporin-2 expression. Nephrol Dial Transplant 2010; 25: 3840-3845.
27. Park SJ, Kim JH, Shin JI: Insight on mechanism of hyponatraemia induced by lowdose intravenous pulse cyclophosphamide. Nephrol Dial Transplant 2010; 25: 3453-3454.
28. Levtchenko EN, Monnens LA: Nephrogenic syndrome of inappropriate antidiuresis. Nephrol Dial Transplant 2010; 25: 2839-2843.
29. Robertson GL: Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 2006; 119:S36-S42.
30. Feldman BJ, Rosenthal SM, Vargas GA: Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005; 352: 1884-1890. (Pubitemid 40627814)
31. Fenske W, Maier SK, Blechschmidt A, et al: Utility and limitations of the traditional diagnostic approach to hyponatremia: A diagnostic study. Am J Med 2010; 123: 652-657.
32. Hannon MJ, Thompson CJ: The syndrome of inappropriate antidiuretic hormone: Prevalence, causes and consequences. Eur J Endocrinol 2010; 162(suppl 1):S5-S12.
33. Chung HM, Kluge R, Schrier RW, Anderson RJ: Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med 1987; 83: 905-908. (Pubitemid 18098166)
34. Cerdá-Esteve M, Cuadrado-Godia E, Chillaron JJ, et al: Cerebral salt wasting syndrome. Eur J Intern Med 2008; 19: 249-254.
35. Milionis HJ, Liamis GL, Elisaf MS: The hyponatremic patient: A systematic approach to laboratory diagnosis. CMAJ 2002; 166: 1056-1062. (Pubitemid 34304651)
36. Green HH, Harrington AR, Valtin H: On the role of antidiuretic hormone in the inhibition of acute water diuresis in adrenal insufficiency and the effects of gluco- and mineralocorticoids in reversing the inhibition. J Clin Invest 1970; 49: 1724-1736.
37. Olchovsky D, Ezra D, Vered I, et al: Symptomatic hyponatremia as a presenting sign of hypothalamic-pituitary disease: A syndrome of inappropriate secretion of antidiuretic hormone (SIADH)-like glucocorticosteroidresponsive condition. J Endocrinol Invest 2005; 28: 151-156. (Pubitemid 43162791)
38. Decaux G, Musch W: Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol 2008; 3: 1175-1184.
39. Arieff AI, Llach F, Massry SG: Neurological manifestations and morbidity of hyponatremia: Correlation with brain water and electrolytes. Medicine 1976; 55: 121-129.
40. Ayus JC, Arieff AI: Abnormalities of water metabolism in the elderly. Semin Nephrol 1996; 16: 277-288. (Pubitemid 26239457)
41. Decaux G, Unger J, Brimioulle S, Mockel J: Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Rapid correction with urea, sodium chloride, and water restriction therapy. JAMA 1982; 247: 471-474. (Pubitemid 12203030)
42. Steele A, Gowrishankar M, Abrahamson S, et al: Postoperative hyponatremia despite near isotonic saline infusion: A phenomenon of desalination. Ann Intern Med 1997; 126: 20-25. (Pubitemid 27021214)
43. Sterns RH, Riggs JE, Schochet SS Jr: Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986; 314: 1535-1542. (Pubitemid 16114683)
44. Sterns RH, Cappuccio JD, Silver SM, Cohen EP: Neurologic sequelae after treatment of severe hyponatremia: A multicenter perspective. J Am Soc Nephrol 1994; 4: 1522-1530.
45. Adrogué HJ, Madias NE: Hyponatremia. N Engl J Med 2000; 342: 1581-1589. (Pubitemid 30340505)
46. Sherlock M, Thompson CJ: The syndrome of inappropriate antidiuretic hormone: Current and future management options. Eur J Endocrinol 2010; 162(suppl 1):S13-S18.
47. Perianayagam A, Sterns RH, Silver SM, et al: DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol 2008; 3: 331-336.
48. Decaux G: Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by long loop diuretics. Nephron 1983; 35: 82-88. (Pubitemid 13033726)
49. Ghali JK: Mechanisms, risks and new treatment options for hyponatremia. Cardiology 2008; 111: 147-157.
50. Perks WH, Walters EH, Tams IP, Prowse K: Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone. Thorax 1979; 34: 324-327. (Pubitemid 9223975)
51. Curtis NJ, van Heyningen C, Turner JJ: Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatremia. Age Ageing 2002; 31: 151-152. (Pubitemid 34413818)
52. Kwon T-H, Laursen UH, Marples D, et al: Altered expression of renal AQPs and Na+ transporters in rats with lithium-induced nephrogenic diabetes insipidus. Am J Physiol Ren Physiol 2000; 279:F552-F564.
53. Grunfeld JP, Rossier BC: Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5: 270-276.
54. Huang E, Feldman BJ, Schwartz D, et al: Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children. J Pediatr 2006; 148: 128-131. (Pubitemid 43098970)
55. Decaux G, Soupart A, Vassart G: Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 2008; 371: 1624-1632. (Pubitemid 351626846)
56. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr: Pharmacology of vasopressin antagonists. Heart Fail Rev 2009; 14: 75-82.
57. Ghali JK, Koren MJ, Taylor JR, et al: Efficacy and safety of oral conivaptan: A V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91: 2145-2152. (Pubitemid 43854997)
58. Annane D, Decaux G, Smith N: Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci 2009; 337: 28-36.
59. Decaux G: Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001; 110: 582-584.
60. Gines P, Wong F, Watson H, et al: Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. Hepatology 2008; 48: 204-213. (Pubitemid 351975545)
61. Soupart A, Gross P, Legros JJ, et al: Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2 receptor antagonist. Clin J Am Soc Nephrol 2006; 1: 1154-1160.
62. Gheorghiade M, Gottlieb SS, Udelson JE, et al: Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006; 97: 1064-1067.
63. Schrier RW, Gross P, Gheorghiade M, et al: Tolvaptan, a selective oral vasopressin V2- receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112. (Pubitemid 44749318)
64. Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA- 985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182-191. (Pubitemid 36042159)
65. Rozen-Zvi B, Yahav D, Gheorghiade M, et al: Vasopressin receptor antagonists for the treatment of hyponatremia: Systematic review and meta-analysis. Am J Kidney Dis 2010; 56: 325-337.
66. Ghali JK, Farah JO, Daifallah S, et al: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther 2009; 3: 253-268.
67. Vaprisol (Conivaptan HCl Injection) Drug Information: Uses, side effects, drug interactions), December 2008. www.rxlist.com/vaprisol- drug.htm (accessed August 25, 2009).
68. Goldsmith SR, Elkayam U, Haught WH, et al: Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: A doseranging pilot study. J Card Fail 2008; 14: 641-647.
69. Wright WL, Asbury WH, Gilmore JL, Samules OB: Conivaptan for hyponatremia in the neurocritical care unit. Neurocrit Care 2009; 11: 6-13.
70. Verbalis JG, Zeltser D, Smith N, et al: Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: Subgroup analysis of a randomized, controlled study. Clin Endocrinol 2008; 69: 159-168. (Pubitemid 351847263)
71. Zeltser D, Rosansky S, van Rensburg H, et al, Conivaptan Study Group: Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007; 27: 447-457. (Pubitemid 47482001)
72. Velez JC, Dopson SJ, Sanders DS, et al: Intravenous conivaptan for the treatment of hyponatremia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: A single center experience. Nephrol Dial Transplant 2010; 25: 1524-1531.
73. Udelson JE, Smith WB, Hendrix GH, et al: Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-2423. (Pubitemid 33108374)
74. Samsca (Tolvaptan): US Prescribing Information. Rockville, Otsuka America Pharmaceutical Inc, 2009.
75. Samsca (Tolvaptan): EU Summary of Product Characteristics. Uxbridge, Otsuka Pharmaceutical Europe Ltd, 2009.
76. Nemerovski C, Hutchinson DJ: Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: A clinical review. Clin Ther 2010; 32: 1015-1032.
77. Berl T, Quittnat-Pelletier F, Verbalis JG, et al, SALTWATER Investigators: Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21: 705-712.
78. Gheorghiade M, Niazi I, Ouyang J, et al: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation 2003; 107: 2690-2696. (Pubitemid 36667242)
79. Gheorghiade M, Gattis WA, O'Connor CM, et al: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004; 291: 1963-1971. (Pubitemid 38544277)
80. Gheorghiade M, Konstam MA, Burnett JC Jr, et al: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343. (Pubitemid 46513234)
81. Konstam MA, Gheorghiade M, Burnett JC Jr, et al: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331. (Pubitemid 46513233)
82. Nemerovski C, Hutchinson DJ: Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: A clinical review. Clin Ther 2010; 32: 1015-1032.
83. Rose BD, Post TW: Clinical Physiology of Acid-Base and Electrolyte Disorders, ed 5. New York, McGraw-Hill, 2001, p 702.
84. Fenske W, Allolio B: The syndrome of inappropriate secretion of antidiuretic hormone: Diagnostic and therapeutic advances. Horm Metab Res 2010; 42: 691-702.